ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC (NCT07671560) | Qiming Wang | 2026-07-01 |
Track ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib automatically
Every clearance here is in the API, with alerts when new ones post.